PDS Biotechnology Corporation · NASDAQ:PDSB

PDS Biotechnology — Technical Presentation (October 2023)

57 slides from PDS Biotechnology's technical presentation, Oct 3, 2023

  1. Slide 1: PDS0101 in HPV16+ Head and Neck Cancer KOL Roundtable

    Slide 1: PDS0101 in HPV16+ Head and Neck Cancer KOL Roundtable

    PDS0101 in HPV16+ Head and Neck Cancer KOL Roundtable NASDAQ: PDSB Precision Designed Science For Immunotherapy October 3, 2023 © 2023 PDS Biotechnology. All Rights Reserved. 1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concernin

  3. Slide 3: Disclaimer

    Slide 3: Disclaimer

    Disclaimer • PDS Biotech is the sponsor of this roundtable • Each panelist is speaking on behalf of PDS Biotech under the terms of a consulting agreement • Information presented is consistent with FDA regulations and guidelines 3

  4. Slide 4: Welcome and Introductions

    Slide 4: Welcome and Introductions

    Welcome and Introductions Dr. Lauren V. Wood 4

  5. Slide 5: Introducing Our Panel

    Slide 5: Introducing Our Panel

    Introducing Our Panel Dr. Ricard Mesía Dr. John Kaczmar Dr. Katharine Price Dr. Glenn Hanna Head of Medical Oncology Associate Professor Medical Associate Professor Assistant Professor, Harvard Catalan Institute of Oncology University of South Carolina Mayo Clinic Comprehensive University and Medica

  6. Slide 6: Today's Agenda

    Slide 6: Today's Agenda

    Today’s Agenda Welcome and Introductions Dr. Lauren V. Wood Current Treatment of HPV16+ HNSCC and Unmet Needs Dr. Ricard Mesía PDS0101 for the Treatment of HPV16+ HNSCC Data to Date Dr. John Kaczmar Plans for Phase 3 Study Dr. Katharine Price Emerging Use of ctDNA in Treatment of HPV+ HNSCC Dr. Glen

  7. Slide 7: Current Treatment of HPV16+ HNSCC and Unmet Needs

    Slide 7: Current Treatment of HPV16+ HNSCC and Unmet Needs

    Current Treatment of HPV16+ HNSCC and Unmet Needs Dr. Ricard Mesía 7

  8. Slide 8: Standard-of-Care in Recurrent/Metastatic HNSCC: ECOG 0-1

    Slide 8: Standard-of-Care in Recurrent/Metastatic HNSCC: ECOG 0-1

    Standard-of-Care in Recurrent/Metastatic HNSCC: ECOG 0-1 KEY OS 12-14 m R/M: recurrent/metastatic • CPS • Performance Score HNSCC: head and neck • Tumor burden Tumor Patient (ECOG) PFS 3-5 m squamous cell carcinoma and growth rate • Comorbidities, age CPS: combined positive score IO: immuno-oncology

  9. Slide 9: What Happened with CPS<1?

    Slide 9: What Happened with CPS<1?

    What Happened with CPS<1? Pembrolizumab vs EXTREME Pembrolizumab + CT vs EXTREME CPS < 1: pembrolizumab alone is detrimental and pembrolizumab + CT is not superior CT: chemotherapy Burtness B, et al. J Clin Oncol. 2022. 9

  10. Slide 10: Baseline Characteristics, KEYNOTE-048

    Slide 10: Baseline Characteristics, KEYNOTE-048

    Baseline Characteristics, KEYNOTE-048 Pembrolizumab Alone vs EXTREME Pembrolizumab + Chemo vs EXTREME Characteristic, n (%) Pembro EXTREME Pembro + Chemo EXTREME N = 301 N = 300 N = 281 N = 278a Age, median (range), years 62 (22-94) 61 (24-84) 61 (20-85) 61 (24-84) Male 250 (83.1) 261 (87.0) 224 (79

  11. Slide 11: The Actual Goals of Therapy in Recurrent/Metastatic Disease

    Slide 11: The Actual Goals of Therapy in Recurrent/Metastatic Disease

    The Actual Goals of Therapy in Recurrent/Metastatic Disease Recurrent/Metastatic Treatment Goal Palliative intent = Only??? • ↑ Survival • ↑ Response rates • ↑ Symptom control • ↑ QoL Improve long-survivors rate 5-yr OS: 15-18% with IOsin CPS≥1 The complete cure of the recurrent/metastatic patient?

  12. Slide 12: Treatment After 1st Line Recurrent/Metastatic: Expectations

    Slide 12: Treatment After 1st Line Recurrent/Metastatic: Expectations

    Treatment After 1st Line Recurrent/Metastatic: Expectations Only 50 to 60% will receive a second line therapy based on what, they received first Harrington K. et al. ASCO Annual meeting 2020 Haddad J Clin Oncol 2023 12

  13. Slide 13: Treatment After 1st Line Recurrent/Metastatic: Expectations

    Slide 13: Treatment After 1st Line Recurrent/Metastatic: Expectations

    Treatment After 1st Line Recurrent/Metastatic: Expectations mOS Can Be Predicted by Response to First Line mPFS to 2L May Range Between 3-6m Psyrri A. et al. Annals of Oncology, 2023, Harrington K. et al. ASCO Annual meeting 2020 13

  14. Slide 14: Unmet Needs in 1st Line Recurrent/Metastatic – HPV16+

    Slide 14: Unmet Needs in 1st Line Recurrent/Metastatic – HPV16+

    Unmet Needs in 1st Line Recurrent/Metastatic – HPV16+ • To improve the rate of long-term survival • To reduce the toxicity of the actual treatments, to improve QoL • To define the best sequence of treatment for specific HPV-related patients with recurrent/metastatic disease. The best option of treat

  15. Slide 15: PDS0101 for the Treatment of HPV16+ HNSCC Data to Date

    Slide 15: PDS0101 for the Treatment of HPV16+ HNSCC Data to Date

    PDS0101 for the Treatment of HPV16+ HNSCC Data to Date Dr. John Kaczmar 15

  16. Slide 16: VERSATILE-002 Key Goal: Improve Survival with PDS0101

    Slide 16: VERSATILE-002 Key Goal: Improve Survival with PDS0101

    VERSATILE-002 Key Goal: Improve Survival with PDS0101 Targeted Immunotherapy • Overall Survival with KEYTRUDA® or KEYTRUDA® + chemo is only 12–14 months in KEYNOTE-048 • 24-month survival rate with KEYTRUDA® or KEYTRUDA® + chemo is only 29% - 31% in KEYNOTE-048 • No difference in survival between HP

  17. Slide 17: VERSATILE-002 Phase 2 Clinical Trial

    Slide 17: VERSATILE-002 Phase 2 Clinical Trial

    VERSATILE-002 Phase 2 Clinical Trial Objective: To Assess the Combination of PDS0101 and KEYTRUDA® in ICI Naïve Subjects with Recurrent or Metastatic HPV-positive HNSCC Key Entry FDA Approved Study Study Partner Criteria for ICI Endpoints Standard of Care Design Naïve Subjects Treatment KEYTRUDA® Op

  18. Slide 18: VERSATILE-002 ICI Naïve Key Demographics and Treatment Exposure

    Slide 18: VERSATILE-002 ICI Naïve Key Demographics and Treatment Exposure

    VERSATILE-002 ICI Naïve Key Demographics and Treatment Exposure Majority of Patients Are CPS 1-19 Demographic ITT Population mITT Population Treatment Exposure (N=55) (N=52) (ITT Population) Age, Median (Min, Max) 64.0 (46, 83) 64.0 (46, 83) Sex, n (%) • Median number of PDS0101 Male 51 (92.7) 48 (9

  19. Slide 19: PDS0101 and KEYTRUDA Combination Demonstrates Promising Patient Survival to Date

    Slide 19: PDS0101 and KEYTRUDA Combination Demonstrates Promising Patient Survival to Date

    PDS0101 and KEYTRUDA® Combination in ICI Naïve HNSCC Demonstrates Promising Patient Survival to Date Median OS Not Yet Estimable Kaplan-Meier Estimates of Overall Survival (OS) (Intent-to-Treat Population) 1.0 0.9 0.8 0.7 12 Month Survival Fraction 0.6 OS Rate – 80% 24 Month OS Rate – 74% 0.5 0.4 0.

  20. Slide 20: PDS0101 and KEYTRUDA Combination Survival vs KEYNOTE-048

    Slide 20: PDS0101 and KEYTRUDA Combination Survival vs KEYNOTE-048

    PDS0101 and KEYTRUDA® Combination in ICI Naïve HNSCC Demonstrates Promising Patient Survival to Date Overall Survival is Primary Endpoint in Planned Phase 3 Study VERSATILE-003 KEYTRUDA® KEYTRUDA® + Chemo PDS0101 + KEYTRUDA® 12-month OS Rate 24-month OS Rate VERSATILE-002 KEYNOTE-048 VERSATILE-002 O

  21. Slide 21: Disease Stabilization or Tumor Reduction in 81% of Patients

    Slide 21: Disease Stabilization or Tumor Reduction in 81% of Patients

    Disease Stabilization or Tumor Reduction in 81% of Patients Tumor Shrinkage in 60% (31/52) with Confirmed Objective Response in 27% (14/52) to Date Best Percentage Change from Baseline in Target Lesions (mITT population) 100 Progression Free Survival 90 80 VERSATILE-002 Months (95% CI) 70 60 PDS0101

  22. Slide 22: No ICI Naïve Subjects Have Grade 4 or 5 Treatment Related Adverse Events

    Slide 22: No ICI Naïve Subjects Have Grade 4 or 5 Treatment Related Adverse Events

    No ICI Naïve Subjects Have Grade 4 or 5 Combination Treatment Related Adverse Events (N=62) 13% (8/62) Subjects have Grade 3 Combination Treatment Related Adverse Events Injection Site Specific AEs Other AEs Preferred Term n (%) Preferred Term n (%) Any Combination-TRAE 49 (79.0) Fatigue 23 (37.1) I

  23. Slide 23: PDS0101 with KEYTRUDA Well Tolerated in VERSATILE-002 to Date

    Slide 23: PDS0101 with KEYTRUDA Well Tolerated in VERSATILE-002 to Date

    PDS0101 with KEYTRUDA® Well Tolerated in VERSATILE-002 to Date Grade 3–5 Treatment Related Adverse Events KEYTRUDA® KEYTRUDA®+ Chemo PDS0101 + KEYTRUDA® VERSATILE-002 13% No Grade 4 or 5 TRAE 72% KEYNOTE-048 (CPS≥1) 17% Subjects (%) *No controlled or comparative studies have been conducted between c

  24. Slide 24: Combination Continues to Show Promising Survival Outcomes in ICI Naïve Subjects

    Slide 24: Combination Continues to Show Promising Survival Outcomes in ICI Naïve Subjects

    Combination of PDS0101 & KEYTRUDA® Continues to Show Promising Survival Outcomes in ICI Naïve subjects PDS0101 with KEYTRUDA® Combination Data Shows Potential Of PDS0101 to Safely Modify the Tumor Microenvironment and Target HPV16-positive HNSCC to Promote Survival • The 24-month OS rate in the ICI

  25. Slide 25: Plans for Phase 3 Study

    Slide 25: Plans for Phase 3 Study

    Plans for Phase 3 Study Dr. Katharine Price 25

  26. Slide 26: VERSATILE-003

    Slide 26: VERSATILE-003

    VERSATILE-003 Designed to Be Confirmatory Trial for ICI Naïve Cohort of Phase 2 VERSATILE-002 Study with Overall Survival as Primary Endpoint A Phase 3 Open-Label, Randomized Study of PDS0101 Plus Pembrolizumab vs Pembrolizumab Alone in First Line Treatment of Immune Checkpoint Inhibitor (ICI) Naïve

  27. Slide 27: VERSATILE-003 Phase 3 Study Design

    Slide 27: VERSATILE-003 Phase 3 Study Design

    VERSATILE-003 Phase 3 Study Design Global Randomized, Controlled Clinical Study with Estimated 90–100 Sites Targeted For the treatment of recurrent or metastatic HPV16-positive HNSCC Indication Primary Overall survival (OS) Endpoint Planned Interim Analysis: Final Analysis: OS OS Enrollment Follow-u

  28. Slide 28: Primary and Secondary Objectives

    Slide 28: Primary and Secondary Objectives

    Primary and Secondary Objectives Primary Objective • Overall survival (OS) between investigational arm (PDS0101 + KEYTRUDA®) vs. control arm (KEYTRUDA®) Secondary Objectives • Progression-free survival (PFS) between the investigational arm vs. control arm per RECIST1.1, BICR • Objective response rat

  29. Slide 29: Safety and Exploratory Objectives

    Slide 29: Safety and Exploratory Objectives

    Safety and Exploratory Objectives Safety Objective • Overall safety between the investigational arm vs control arm Exploratory Objectives • Disease Control Rate (DCR) between the investigational arm vs control arm • PFS2 between the investigational arm vs control arm • iORR, iPFS, and iDOR between t

  30. Slide 30: Study Treatment Schedule

    Slide 30: Study Treatment Schedule

    Study Treatment Schedule Study Treatments • PDS0101 1mL subcutaneous every 3 weeks • Pembrolizumab 200mg intravenous every 3 weeks Treatment Schedule Investigational Arm Cycles 1-4 Cycles 5-11 Cycle 12 Cycles 13-35 PDS0101 + Pembrolizumab PDS0101 + Pembrolizumab Pembrolizumab monotherapy Pembrolizum

  31. Slide 31: Key Inclusion Criteria

    Slide 31: Key Inclusion Criteria

    Key Inclusion Criteria 1. Subject is ≥18 years of age 2. History of histologically- or cytologically-confirmed diagnosis of squamous cell cancer of the head and neck (HNSCC) 3. Unresectable recurrent and/or metastatic measurable disease with confirmation of at least 1 lesion that is considered a tar

  32. Slide 32: Key Exclusion Criteria

    Slide 32: Key Exclusion Criteria

    Key Exclusion Criteria 1. Prior therapy with HPV-specific immunotherapy including therapeutic cancer vaccines and cellular immunotherapy. Note: subjects who have received prophylactic HPV vaccines are eligible for enrollment 2. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with

  33. Slide 33: Timeline to Registrational Trial Initiation

    Slide 33: Timeline to Registrational Trial Initiation

    Timeline to Registrational Trial Initiation Worldwide Randomized, Controlled Clinical Study to Be Initiated Q4 2023 PDS0101 + KEYTRUDA® in Recurrent or Metastatic HPV16-Positive HNSCC 2Q 2022 3Q 2022 1Q 2023 2Q 2023 3Q 2023 4Q 2023 • FDA Fast Track • Successful EOP2 • Completed • Completed CMC- • Re

  34. Slide 34: Emerging Use of ctDNA in Treatment of HPV+ HNSCC

    Slide 34: Emerging Use of ctDNA in Treatment of HPV+ HNSCC

    Emerging Use of ctDNA in Treatment of HPV+ HNSCC Dr. Glenn Hanna 34

  35. Slide 35: Pre-treatment HPV ctDNA Detection

    Slide 35: Pre-treatment HPV ctDNA Detection

    Pre-treatment HPV ctDNA Detection Rettig EM, et al. JAMA Otolaryngol Head Neck Surg 2022 35

  36. Slide 36: HPV ctDNA Clearance During Treatment

    Slide 36: HPV ctDNA Clearance During Treatment

    HPV ctDNA Clearance During Treatment ctHPV16DNA levels increased after starting CRT and later declined * N=87 (84%) received 80% of patients had no detectable ctHPV16DNA by the end of CRT deintensified CRT on a clinical trial (60 Gy) No patients with >95% viral clearance (from baseline) by week 4 de

  37. Slide 37: HPV ctDNA Clearance During Treatment

    Slide 37: HPV ctDNA Clearance During Treatment

    HPV ctDNA Clearance During Treatment Low baseline ctHPV16DNA (≤200 copies/mL) had lower tumor HPV copy number Those with low tumor HPV copy number (≤5 copies/haploid genome) had HPV integration Low baseline ctHPV16DNA → HPV integration → adverse tumor genomics Chera BS, et al. Clin Cancer Res 2019 3

  38. Slide 38: HPV ctDNA Clearance During Treatment

    Slide 38: HPV ctDNA Clearance During Treatment

    HPV ctDNA Clearance During Treatment Favorable ctHPV16DNA profile: >200 copies/mL baseline and >95% viral clearance by week 4 Chera BS, et al. Clin Cancer Res 2019 38

  39. Slide 39: Risk Stratifying HPV+ Oropharyngeal Cancer

    Slide 39: Risk Stratifying HPV+ Oropharyngeal Cancer

    Risk Stratifying HPV+ Oropharyngeal Cancer HPV+, ≤10 pack-year smoker 0-1 lymph node HPV-, >10 pack-year smoker, T4 tumors, multiple and large lymph nodes Trend towards de-intensification TORS + Radiation (60 Gy), or lower dose chemoradiation, or induction chemotherapy followed by lower dose radiati

  40. Slide 40: Risk Stratifying HPV+ Oropharyngeal Cancer

    Slide 40: Risk Stratifying HPV+ Oropharyngeal Cancer

    Risk Stratifying HPV+ Oropharyngeal Cancer What do we do for the intermediate risk group? 63M (former smoker) with HPV+ left tonsil SCC with cT4N1 (stage III, AJCC 2017 8th ed) disease? Standard bolus cisplatin with chemoradiation or can we de-intensify at all? What can we use to risk stratify him b

  41. Slide 41: ReACT Study: Risk-adapted Therapy Using ctHPV DNA Profile

    Slide 41: ReACT Study: Risk-adapted Therapy Using ctHPV DNA Profile

    Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile ReACT Study Phase II, non-randomized, exploratory study 2-year PFS of 75% from RTOG 1016 for the favorable intermediate-risk group N=45 evaluable pts provides 80% power to improve PFS to 86% at 2-years (0.5

  42. Slide 42: ReACT Study: Risk-adapted Therapy Using ctHPV DNA Profile

    Slide 42: ReACT Study: Risk-adapted Therapy Using ctHPV DNA Profile

    Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile ReACT Study Failure to clear TTMV-HPV DNA by 95% at week 4-5, no de-escalation (higher risk?) Hanna GJ, Schoenfeld JD, et al. Accruing 2022 42

  43. Slide 43: HPV ctDNA and Response to Induction

    Slide 43: HPV ctDNA and Response to Induction

    HPV ctDNA and Response to Induction 39M (Never Smoker) with de novo Metastatic HPV+ BOT SCC with Lung Metastases, After 1-Cycle of Chemoimmunotherapy TTMV-HPV DNA Nearly Clears…Completed 3-cycles, Now on to Consolidative CRT… Hanna GJ, patient example 43

  44. Slide 44: HPV ctDNA and Response to Surgery

    Slide 44: HPV ctDNA and Response to Surgery

    HPV ctDNA and Response to Surgery Routman DM, et al. Int J Radiat Oncol Biol Phys 2022 44

  45. Slide 45: HPV ctDNA During Surveillance

    Slide 45: HPV ctDNA During Surveillance

    HPV ctDNA During Surveillance Worse outcomes for those with two consecutively positive ctHPVDNA results post-treatment Among patients with recurrence, ctHPVDNA positivity often predated detection of recurrence on imaging or biopsy Chera BS, et al. J Clin Oncol 2020 45

  46. Slide 46: HPV ctDNA During Surveillance

    Slide 46: HPV ctDNA During Surveillance

    HPV ctDNA During Surveillance In follow-up, PPV is 97% with further cancer events identified Berger B, Hanna GJ, et al. Clin Cancer Res 2021 46

  47. Slide 47: HPV ctDNA During Surveillance

    Slide 47: HPV ctDNA During Surveillance

    HPV ctDNA During Surveillance Hanna GJ, et al. Clin Cancer Res 2023 47

  48. Slide 48: HPV ctDNA During Surveillance

    Slide 48: HPV ctDNA During Surveillance

    HPV ctDNA During Surveillance Rettig EM, Hanna GJ, et al. Accrual completed in 2022 48

  49. Slide 49: HPV ctDNA Conclusions (or More Questions)…

    Slide 49: HPV ctDNA Conclusions (or More Questions)…

    HPV ctDNA Conclusions (or More Questions)… Should HPV ctDNA be incorporated into routine surveillance for all HPV-positive oropharyngeal cancer patients? Is this ready for inclusion in the NCCN® guidelines? Can HPV ctDNA results guide the choice of whether to pursue additional surveillance imaging b

  50. Slide 50: PDS0101 + KEYTRUDA in ICI Refractory Subjects

    Slide 50: PDS0101 + KEYTRUDA in ICI Refractory Subjects

    PDS0101 + KEYTRUDA® in ICI Refractory Subjects Dr. Lauren V. Wood 50

  51. Slide 51: Assessing the Role of PDS0101 in Extending Survival Without a Control Arm

    Slide 51: Assessing the Role of PDS0101 in Extending Survival Without a Control Arm

    Assessing the Role of PDS0101 in Extending Survival in the Absence of a VERSATILE-002 KEYTRUDA® Control Arm Evaluation of PDS0101 + KEYTRUDA® in HPV16-positive head and neck patients who have failed/progressed on KEYTRUDA® therapy (ICI Refractory) • Evaluation of the combination of PDS0101 and KEYTR

  52. Slide 52: VERSATILE-002 ICI Refractory Cohort

    Slide 52: VERSATILE-002 ICI Refractory Cohort

    VERSATILE-002 ICI Refractory Cohort Phase 2, Open-Label, Non-Randomized, Adaptive Design Study Evaluating the Combination of PDS0101 and KEYTRUDA® Population, Treatment Exposure, Methods and Limitations and Primary Endpoint Key Entry Criteria for ICI Refractory Subjects ITT and mITT Population (N=21

  53. Slide 53: Survival Rates Demonstrate Potential Contribution of PDS0101

    Slide 53: Survival Rates Demonstrate Potential Contribution of PDS0101

    Survival Rates Demonstrate Potential Contribution of PDS0101 to Survival in Advanced Head and Neck Cancer PDS0101 + KEYTRUDA Shows Promising Survival Benefit even in ICI Refractory Patients 12-month Overall Survival Rate Progression 12-month Overall Survival Rate First-line R/M HNSCC ICI Refractory

  54. Slide 54: No ICI Refractory Subjects Have Grade 4 or 5 Treatment Related Adverse Events

    Slide 54: No ICI Refractory Subjects Have Grade 4 or 5 Treatment Related Adverse Events

    No ICI Refractory Subjects Have Grade 4 or 5 Combination Treatment Related Adverse Events (N=25) 4% (1/25) Subjects Have Grade 3 Combination Treatment Related Adverse Events Injection Site Specific AEs Other AEs Preferred Term n (%) Preferred Term n (%): Events Any Combination-TRAE 21 (84.0) Fatigue

  55. Slide 55: VERSATILE-002 Results Support Initiation of Phase 3 Trial in ICI Naïve R/M HNSCC

    Slide 55: VERSATILE-002 Results Support Initiation of Phase 3 Trial in ICI Naïve R/M HNSCC

    VERSATILE-002 Study Results To-Date Support Initiation of Phase 3 Clinical Trial in ICI Naïve R/M HNSCC • Promising survival data in target population for phase 3 study • 24-month survival rate of 74% in HPV16-positive ICI naïve head and neck cancer patients; published results of 29% with ICI therap

  56. Slide 56: Panel Discussion

    Slide 56: Panel Discussion

    Panel Discussion 56

  57. Slide 57: Closing Remarks

    Slide 57: Closing Remarks

    Closing Remarks Dr. Lauren V. Wood 57

Source: Internet Archive copy of pdsbiotech.com

More decks from PDS Biotechnology Corporation

All 90 PDS Biotechnology decks